Medullary Thyroid Cancer (MTC)NCT07142005
Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer
An observational study of Medullary Thyroid Cancer (MTC) and Cultural Adaptation, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To find good information about medullary thyroid cancer that is easy to understand and reliable, so researchers aim to design some new educational materials to help. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Medullary Thyroid Cancer (MTC), Cultural Adaptation
- What is being tested?
- Interviews
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Aug 2025to 31 Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: MD Anderson Cancer Center
Who may be able to join
- Provision of signed and dated informed consent form
- Males and females; Age: ≥18 years old
- Identified ethnicity as "Hispanic" or "Latino/Latina"
- Ability to read, write, and speak Spanish
- Those who are pregnant are eligible to participate
- Have or will face this decision, including: a. Participant/survivor - who has medullary thyroid carcinoma, as determined by a clinician or documented in Multi-Institutional Medullary Thyroid Cancer Collaborative Registry; b. Caregiver/family member - of Participant/survivor who has medullary thyroid carcinoma, as nominated by the Participant/survivor
Who cannot join
- Those < age 18
- Ethnic identity as non-Hispanic or non-Latino/a individual
- Individuals with cognitive or psychological impairment (e.g., depression, anxiety, severe mental illness as documented in the registry
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
MD Anderson Cancer Center
Houston, Texas, 77030
Elizabeth Grubbs, MD, 713-792-0665, eggrubbs@mdanderson.org
Elizabeth Grubbs, MD
About this study
To find good information about medullary thyroid cancer that is easy to understand and reliable, so researchers aim to design some new educational materials to help.
Read the detailed description
Primary Objectives
- To co-develop a culturally-adapted educational tool for the Latino/Latina MTC population using the previously developed MTCEducate.org as a framework. (Phase 1)
- To test, refine, and produce a culturally adapted educational prototype and is intended to assess participants' understanding after reviewing the decision aid as part of the iterative testing and refinement process (Phase 2)
Secondary Objectives
- To assess the tool's acceptability post-production among a broader population of Latino(a) MTC participants and caregivers using the Ottawa Acceptability Scale (Phase 3)
- To disseminate the educational tool to a broader population of Latino(a)s
- To summarize the clinico-demographics of educational tool users
- Being tested
- Interviews
- Medical subject headings
- Carcinoma, Medullary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InterviewsOther
- Questionnaires/Survey Measures
- Qualitative Instruments
What is being measured
The primary outcome is the main question the study is designed to answer.
Questionnaires/Survey Measures
Measured: Through study completion; an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Aug 2025
- Study start15 Aug 2025
- Primary completion31 Mar 2028 (estimated)
- Study completion31 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Medullary Thyroid Cancer (MTC)Studies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Elizabeth Grubbs, MD, Principal investigator, eggrubbs@mdanderson.org
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07142005
- Sponsor's protocol ID
- 2025-0198
- Other IDs
- NCI-2025-04498
- Status last verified
- Sep 2026
- First submitted
- 20 Jun 2025
- Last updated
- 25 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer
- ClinicalTrials.gov ID
- NCT07142005
- Acronym / sponsor ID
- 2025-0198
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 15 Aug 2025 (actual)
- Primary completion
- 31 Mar 2028 (estimated)
- Study completion
- 31 Mar 2028 (estimated)
- First posted
- 26 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To find good information about medullary thyroid cancer that is easy to understand and reliable, so researchers aim to design some new educational materials to help.
Detailed description
Primary Objectives
- To co-develop a culturally-adapted educational tool for the Latino/Latina MTC population using the previously developed MTCEducate.org as a framework. (Phase 1)
- To test, refine, and produce a culturally adapted educational prototype and is intended to assess participants' understanding after reviewing the decision aid as part of the iterative testing and refinement process (Phase 2)
Secondary Objectives
- To assess the tool's acceptability post-production among a broader population of Latino(a) MTC participants and caregivers using the Ottawa Acceptability Scale (Phase 3)
- To disseminate the educational tool to a broader population of Latino(a)s
- To summarize the clinico-demographics of educational tool users
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- MD Anderson Cancer Center
Key inclusion criteria (6 listed)
- Provision of signed and dated informed consent form
- Males and females; Age: ≥18 years old
- Identified ethnicity as "Hispanic" or "Latino/Latina"
- Ability to read, write, and speak Spanish
- Those who are pregnant are eligible to participate
Key exclusion criteria (3 listed)
- Those < age 18
- Ethnic identity as non-Hispanic or non-Latino/a individual
- Individuals with cognitive or psychological impairment (e.g., depression, anxiety, severe mental illness as documented in the registry
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Interviews* Questionnaires/Survey Measures * Qualitative Instruments | Other | – |
Primary outcome
Questionnaires/Survey Measures
Time frame: Through study completion; an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2026.
- MD Anderson Cancer CenterLink provided by the sponsor.
Related trials for Medullary Thyroid Cancer (MTC)
RecruitingObservational study
Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer
Non-Medullary Thyroid Cancer
Active, not recruitingObservational study
Natural History Study of Children and Adults With Medullary Thyroid Cancer
Medullary Thyroid Cancer
RecruitingObservational study
68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC )
RecruitingPhase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Active, not recruitingPhase 2
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
SMARCB1-Deficient Malignancies, Epithelioid Sarcoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Elizabeth Grubbs, MD principal investigator
eggrubbs@mdanderson.org
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Medullary Thyroid Cancer (MTC) and Cultural Adaptation, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Elizabeth Grubbs, MD (713-792-0665, eggrubbs@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Questionnaires/Survey Measures (time frame: Through study completion; an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026.